NOVAFED
Clinical safety rating
cautionComprehensive clinical and safety monograph for NOVAFED (NOVAFED).
Novafed contains pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
| Metabolism | Pseudoephedrine is partially metabolized in the liver by N-demethylation to an inactive metabolite. It is excreted primarily unchanged in urine (70-90%). |
| Excretion | Renal elimination of unchanged drug and metabolites; approximately 60-70% of a dose is excreted in urine as unchanged pseudoephedrine within 24 hours; the remainder is metabolized hepatically and excreted renally; minimal biliary/fecal elimination (<5%). |
| Half-life | Terminal elimination half-life: 4-8 hours (mean 5-6 hours); prolonged in renal impairment (up to 20 hours) and with urinary alkalinization; in patients with normal renal function, steady-state is achieved after 2-3 days of every-6-hour dosing. |
| Protein binding | Approximately 20-25% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Apparent volume of distribution (Vd): 2.5-3.5 L/kg; indicates extensive tissue distribution (e.g., into respiratory mucosa, CNS); Vd is increased in obesity. |
| Bioavailability | Oral bioavailability: approximately 100% for immediate-release tablets; pseudoephedrine is well absorbed with high systemic availability; extended-release forms have similar extent of absorption but with slower rate. |
| Onset of Action | Oral administration: 15-30 minutes for decongestant effect; peak effect at 1-2 hours. |
| Duration of Action | Duration: 4-6 hours with immediate-release formulation; extended-release formulations (e.g., 12-hour or 24-hour) provide prolonged effect; clinical note: tachyphylaxis may develop with chronic use; duration is shorter in acidic urine and prolonged in alkaline urine. |
| Molecular Weight | 165.23 Da (pseudoephedrine) |
1-2 capsules orally every 12 hours; each capsule contains pseudoephedrine HCl 120 mg and dextromethorphan HBr 30 mg.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl 30-50 mL/min: administer every 12 hours; CrCl 10-29 mL/min: administer every 24 hours; CrCl <10 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: administer every 12 hours; Child-Pugh Class C: not recommended. |
| Pediatric use | Children 6-12 years: 1/2 capsule orally every 12 hours; children <6 years: not recommended. |
| Geriatric use | Initiate at lower end of dosing range (1 capsule every 12 hours) due to increased sensitivity and potential for adverse effects; monitor renal function. |
| 1st trimester | Avoid in first trimester unless benefit outweighs risk; studies show congenital anomalies with pseudoephedrine. |
| 2nd trimester | Use with caution; may reduce uteroplacental blood flow. |
| 3rd trimester | Avoid near term; associated with uterine irritability and fetal tachycardia. |
Clinical note
Comprehensive clinical and safety monograph for NOVAFED (NOVAFED).
| Placental transfer | Pseudoephedrine crosses placenta; fetal plasma concentrations approximately 70% of maternal. |
| Breastfeeding | Pseudoephedrine and other components can reduce milk supply; monitor infant for irritability and sleep disturbance. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Inadequate human data; animal studies show no teratogenicity at therapeutic doses. Second/third trimester: Potential for uterine artery vasoconstriction reducing placental perfusion; risk of fetal tachycardia. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate. In pregnancy, assess fetal heart rate and uterine activity; consider fetal non-stress test if prolonged use. |
| Fertility Effects | No known significant effect on fertility. Alpha-adrenergic agonists may alter uterine blood flow but no evidence of direct fertility impairment. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Severe hypertensionCoronary artery diseaseConcurrent MAO inhibitor therapyAngle-closure glaucomaUrinary retentionThyrotoxicosis
| Precautions | Use with caution in patients with hypertension, cardiovascular disease, diabetes, glaucoma, hyperthyroidism, prostatic hypertrophy, and in elderly. May cause insomnia, nervousness, and elevated blood pressure. |
| Food/Dietary | Avoid concurrent use with caffeinated beverages or foods as they may increase nervousness and insomnia. Alcohol should be avoided as it can exacerbate side effects. No significant food-drug interactions with other items. |
| Clinical Pearls | NOVAFED contains pseudoephedrine and is contraindicated in patients with severe hypertension or coronary artery disease. Monitor blood pressure closely. Onset of action is 30-60 minutes; do not exceed 240 mg/day. Avoid use with MAOIs or within 14 days of stopping them. |
| Patient Advice | Do not crush or chew extended-release tablets. · Stop use if you experience rapid heartbeat, dizziness, or difficulty urinating. · Avoid taking close to bedtime to prevent insomnia. · Do not take with other cold or allergy medications containing decongestants. · Consult a doctor if symptoms persist after 7 days or are accompanied by fever. |
Loading safety data…